Meeting Banner
Abstract #0045

The DCE-MRI ╬┤Ktrans Biomarker Provides Early Prediction of Soft-Tissue Sarcoma Response to Anti-Angiogenic Therapy

Janelle M. Meyer1, Brooke R. Beckett1, Xin Li1, Luminita A. Tudorica1, Aneela Afzal1, Stephanie Hemmingson1, Yiyi Chen1, Megan L. Holtorf1, William J. Woodward1, Charles S. Springer1, Christopher W. Ryan1, Wei Huang1

1Oregon Health & Science University, Portland, OR, United States

Nine soft-tissue sarcoma patients underwent DCE-MRI scans during the course of a phase I trial of antiangiogenic potentiatiated preoperative chemoradiotherapy. MRI data were acquired before therapy, after two weeks of antiangiogenic therapy only, and after eight more weeks of antiangiogenic therapy plus chemoradiotherapy. The % changes in tumor ROI and histogram median Ktrans values after two weeks provided superior early prediction of therapy pathologic response compared to those in tumor size, ADC, and other DCE-MRI parameters. ROI and median Ktrans changes after two weeks also exhibited a linear relationship with the % necrosis at surgery after ten weeks.